Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of BBP-418 (ribitol) in LGMD2I
2023-503379-33-01Phase 3Authorised
- Sponsor
- ML Bio Solutions
- Start
- Jan 2024
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 3, randomised, double-blind trial in limb-girdle muscular dystrophy type 2I (LGMD2I) comparing BBP-418 (ribitol) with Placebo (2 arms). Primary endpoints: Change from baseline in NSAD at 36 months, Frequency and severity of TEAEs and TESAEs and 3 more. Planned start Jan 2024; status: authorised.
02
Drugs
ribitol
03
Conditions
limb-girdle muscular dystrophy type 2I (LGMD2I)
Beyond the preview
Go deeper on 2023-503379-33-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503379-33-01.